查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089697

美國藥品CDMO（合約開發和生產組織）市場：市場規模、佔有率和趨勢分析（按類型、產品、服務、工作流程、治療領域和最終用途分類），細分市場預測（2026-2033年）

U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Services, By Workflow, By Therapeutic Area, By End-use, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國製藥CDMO（合約研發生產組織）市場概述

美國醫藥CDMO市場預計到2025年將達到388億美元，到2026年將成長到412億美元，到2033年將擴大到653億美元，2026年至2033年的複合年成長率為6.8%。

受生物製藥、生物相似藥和先進療法的開發、藥物研發外包需求的成長以及臨床試驗活動活性化和在研產品線擴張的推動，美國製藥CDMO市場持續成長。在美國市場，生物製藥、生物相似藥以及細胞療法和基因療法等先進療法正經歷顯著成長，這進一步刺激了對專業CDMO服務的需求。

開發和生產這些療法需要先進的能力，例如一次性生物製程系統、病毒載體生產以及個人化醫療方面的專業知識，但許多製藥公司缺乏這些內部能力。美國生物製藥、生物相似藥以及先進的細胞和基因療法市場的顯著成長，推動了對專業CDMO服務的需求。 CDMO提供基礎設施、監管知識和創新平台，以加速研發並滿足FDA標準。隨著美國生技藥品和生物相似藥獲批數量的增加，CDMO正成為擴大生產規模、確保供應鏈韌性以及加快複雜高價值療法上市速度的關鍵合作夥伴。

此外，為了降低成本、縮短前置作業時間並專注於研發和行銷等核心業務，美國製藥公司擴大將藥物研發和生產外包給合約研發產量組織（CDMO）。構成美國創新主體的中小型生技公司可以透過外包獲得專業知識、創新技術和監管支持，而無需進行大量的基礎設施投資。 CDMO 正在成為不斷發展的製藥價值鏈中不可或缺的合作夥伴，提供靈活的生產能力、擴充性以及符合美國食品藥物管理局（FDA）嚴格標準的能力。隨著生物製藥、細胞和基因療法以及特殊製劑的日益複雜化，這一趨勢預計將進一步加速。美國是臨床研究領域的全球領導者，目前有數千項臨床試驗正在進行中，這得益於其強大的生物技術和製藥生態系統。

開發平臺中創新藥物數量的不斷成長，尤其是在腫瘤、罕見疾病和免疫療法領域，推動了對CDMO服務在臨床前、臨床和商業化各個階段的需求。 CDMO在製劑開發、臨床試驗樣本製備、分析測試和監管申報方面提供至關重要的專業知識。隨著小規模生物技術公司在缺乏內部生產設施的情況下不斷推進創新，它們對CDMO的依賴日益加深，以縮短產品上市時間、降低風險並確保符合不斷變化的FDA指南，這進一步鞏固了CDMO在製藥行業中的關鍵作用。

目錄

第1章：分析方法和範圍

第2章執行摘要

第3章：美國醫藥CDMO（合約研發產量組織）市場：影響因素、趨勢與範圍

  • 市場歷史及展望
  • 市場動態
  • 研發支出分析
  • 產業特定生態系分析
  • 科技情勢
  • 臨床試驗數量分析（2025 年）
  • 價格分析
  • 分析關稅和貿易協定的影響
  • 價值鏈分析
  • 市場分析工具

第4章：美國製藥CDMO（合約開發和生產組織）市場：按類型分類的估算和趨勢分析

  • 美國製藥CDMO（合約開發和生產組織）市場：按類型分類的趨勢分析
  • 美國醫藥CDMO（合約開發和生產組織）市場估算和預測：按類型分類（2021-2033年）
  • 低分子化合物
    • 品牌
    • 非專利的
  • 聚合物化合物
    • 生物製劑
    • 生物相似藥

第5章：美國藥品CDMO（合約開發和生產組織）市場：按產品類別分類的估算和趨勢分析

  • 美國醫藥合約研發生產力組織 (CDMO) 市場：按產品類別分類的趨勢分析
  • 美國藥品CDMO（合約開發和生產組織）市場估算與預測：按產品類別分類（2021-2033年）
  • 藥物原料藥（API）
    • 常規藥用原料藥
    • 高效活性原料藥（HP-APIs）
    • 生物製劑
    • 其他
  • 配方
    • 口服固體製劑
    • 半固態製劑
    • 液體
    • 其他

第6章：美國製藥CDMO（合約開發和生產組織）市場：按服務類型分類的估算和趨勢分析

  • 美國醫藥CDMO（合約開發和生產組織）市場：按服務類型分類的趨勢分析
  • 美國醫藥CDMO（合約開發和生產組織）市場估算和預測：按服務類型分類（2021-2033年）
  • 合約開發
    • 預配方設計、配方開發服務
    • 製程開發與最佳化
    • 分析測試、方法驗證
    • 擴大規模，技術轉移
  • 契約製造
    • API生產
    • 藥品製劑的生產
  • 包裝和標籤
  • 醫藥事務
  • 其他

第7章：美國製藥CDMO（合約開發和生產組織）市場：按工作流程分類的估算和趨勢分析

  • 美國製藥CDMO（合約開發和生產組織）市場：按工作流程分類的趨勢分析
  • 美國醫藥CDMO（合約開發和生產組織）市場估算和預測：按工作流程分類（2021-2033年）
  • 臨床階段
  • 市場啟動階段

第8章：美國醫藥CDMO（合約開發和生產組織）市場：按治療領域分類的估算和趨勢分析

  • 美國醫藥CDMO（合約開發和生產組織）市場：按治療領域分類的趨勢分析
  • 美國醫藥CDMO（合約開發和生產組織）市場估算和預測：按治療領域分類（2021-2033年）
  • 瘤
  • 感染疾病
  • 神經病變
  • 心血管疾病
  • 代謝性疾病
  • 自體免疫疾病
  • 呼吸系統疾病
  • 眼科
  • 消化系統疾病
  • 整形外科疾病
  • 牙科疾病
  • 其他

第9章：美國製藥CDMO（合約開發和生產組織）市場：按最終用途分類的估算和趨勢分析

  • 美國醫藥CDMO（合約開發和生產組織）市場：按最終用途分類的趨勢分析
  • 美國醫藥CDMO（合約開發和生產組織）市場估算和預測：按最終用途分類（2021-2033年）
  • 小規模製藥公司
  • 中型製藥公司
  • 大型製藥公司

第10章 競爭格局

  • 主要公司分類
    • 市場領導
    • 新興企業
  • 市場佔有率及評估分析：熱力圖分析（2025 年）
  • 公司簡介
    • Thermo Fisher Scientific, Inc
    • Lonza
    • Recipharm AB
    • Catalent, Inc
    • WuXi AppTec, Inc
    • Samsung Biologics
    • Piramal Pharma Solutions
    • Siegfried Holding AG
    • Corden Pharma International
    • Cambrex Corporation
    • Delpharm
    • Jubilant Pharmova/HollisterStier
    • Eurofins CDMO
    • Almac Pharma Services
Product Code: GVR-4-68040-754-9

U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Summary

The U.S. pharmaceutical CDMO market size was valued at USD 38.8 billion in 2025 and is projected to grow from USD 41.2 billion 2026 to USD 65.3 billion by 2033, at a CAGR of 6.8% from 2026 to 2033. The U.S. pharmaceutical CDMO is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion. The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced therapies such as cell and gene therapies, fueling demand for specialized CDMO services.

Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house. The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house. CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

In addition, to cut expenses, shorten turnaround times, and concentrate on core skills like research and development and marketing, pharmaceutical corporations in the U.S. are increasingly contracting with CDMOs to handle drug development and manufacture. Small and mid-sized biotech companies, which make up the majority of the U.S. innovation scene, can obtain specialized knowledge, innovative technologies, and regulatory support through outsourcing without making significant infrastructure investments. CDMOs are essential partners in the changing pharmaceutical value chain because they provide flexible capacity, scalability, and compliance with strict FDA standards. As biologics, cell and gene therapies, and specialty medication formulations become more sophisticated, this trend is expected to speed up. U.S. leads globally in clinical research, with thousands of active clinical trials supported by a robust biotech and pharmaceutical ecosystem.

The growing number of innovative drugs in the pipeline, particularly in oncology, rare diseases, and immunotherapies, drives demand for CDMO services across preclinical, clinical, and commercial stages. CDMOs provide essential expertise in formulation development, manufacturing clinical trial material, analytical testing, and regulatory submissions. As small biotech firms dominate innovation but lack in-house production facilities, they increasingly rely on CDMOs to accelerate time-to-market, reduce risks, and ensure compliance with evolving FDA guidelines, reinforcing their critical role in the pharmaceutical landscape.

U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Pharmaceutical Contract Development and Manufacturing Organization market report based on type, product, service, workflow, therapeutic area, and end-use.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
    • Branded
    • Generic
  • Large Molecule
    • Biologics
    • Biosimilar
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • API
    • Traditional Active Pharmaceutical Ingredient (Traditional API)
    • Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • Biologics
    • Others
  • Drug Product
    • Oral solid dose
    • Semi-solid dose
    • Liquid dose
    • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
    • Pre-formulation & Formulation Development Services
    • Process Development & Optimization
    • Analytical Testing & Method Validation
    • Scale-up & Tech Transfer
  • Contract Manufacturing
    • API Manufacturing
    • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Others
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Pharmaceutical Companies
  • Medium Pharmaceutical Companies
  • Large Pharmaceutical Companies

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Services
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
  • 3.3. R&D Spending Analysis
  • 3.4. Industry Ecosystem Analysis
    • 3.4.1. Demand Analysis
    • 3.4.2. Supply Chain Analysis
  • 3.5. Technology Landscape
  • 3.6. Clinical Trial Volume Analysis, 2025
  • 3.7. Pricing Analysis
  • 3.8. Tariff and Trade Agreement Impact Analysis
  • 3.9. Value Chain Analysis
    • 3.9.1. Supply Trends
    • 3.9.2. Demand Trends
  • 3.10. Market Analysis Tools
    • 3.10.1. Porter's Five Force Analysis
    • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Type: Segment Dashboard
  • 4.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Type: Movement Analysis
  • 4.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Branded
      • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Generic
      • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilar
      • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Product: Segment Dashboard
  • 5.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Product: Movement Analysis
  • 5.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
  • 5.4. API
    • 5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Biologics
      • 5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Drug Product
    • 5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Oral Solid Dose
      • 5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Semi-Solid Dose
      • 5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Liquid Dose
      • 5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Service: Segment Dashboard
  • 6.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Service: Movement Analysis
  • 6.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Pre-formulation & Formulation Development Services
      • 6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Process Development & Optimization
      • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Analytical Testing & Method Validation
      • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Scale-up & Tech Transfer
      • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. API Manufacturing
      • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Finished Drug Products Manufacturing
      • 6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Packaging and Labelling
    • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Regulatory Affairs
    • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Workflow Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Workflow: Segment Dashboard
  • 7.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Workflow: Movement Analysis
  • 7.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 7.4. Clinical
    • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Commercial
    • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Therapeutic Area: Segment Dashboard
  • 8.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Therapeutic Area: Movement Analysis
  • 8.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Neurological Disorders
    • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Cardiovascular Diseases
    • 8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Metabolic Disorders
    • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Autoimmune Diseases
    • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Respiratory Diseases
    • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Ophthalmology
    • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Gastrointestinal Disorders
    • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Orthopedic Diseases
    • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.14. Dental Diseases
    • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.15. Others
    • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: End-Use Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By End-Use: Segment Dashboard
  • 9.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By End-Use: Movement Analysis
  • 9.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates & Forecasts, By End-Use, 2021 - 2033 (USD Million)
  • 9.4. Small Pharmaceutical Companies
    • 9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medium Pharmaceutical Companies
    • 9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Large Pharmaceutical Companies
    • 9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Key Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Thermo Fisher Scientific, Inc
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Lonza
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Recipharm AB
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Catalent, Inc
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. WuXi AppTec, Inc
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Samsung Biologics
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Piramal Pharma Solutions
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Siegfried Holding AG
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Corden Pharma International
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Cambrex Corporation
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Delpharm
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Jubilant Pharmova / HollisterStier
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Eurofins CDMO
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Almac Pharma Services
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 5 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 US Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Estimates and Forecasts, by End-Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2025 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2025 (USD Billion)
  • Fig. 16 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Type outlook and key takeaways
  • Fig. 20 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Type movement analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Product outlook and key takeaways
  • Fig. 28 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Product movement analysis
  • Fig. 29 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Service outlook and key takeaways
  • Fig. 40 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Service movement analysis
  • Fig. 41 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Pre-formulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Workflow outlook and key takeaways
  • Fig. 53 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Workflow movement analysis
  • Fig. 54 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Therapeutic Area outlook and key takeaways
  • Fig. 57 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: Therapeutic Area movement analysis
  • Fig. 58 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: End-Use outlook and key takeaways
  • Fig. 71 U.S. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market: End-Use movement analysis
  • Fig. 72 Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key company categorization
  • Fig. 77 Service heat map analysis
  • Fig. 78 Strategic framework